

UNIVERSITY COLLEGE



LONDON

26TH JUNE - 14TH JULY
XYNAH MOHSINI



With Rhod Fiorini and other UCL professors



University College London every year host hundreds of students from all over the world undertaking range of modules as a part of the Summer School

- clinical trials module with 10 students from around the world that included 3 weeks of lectures, case studies and discussions about trials about prostate cancer, diabetes, Add-Aspirin trials.



Add-Aspirin was the trial we focused on mainly. It is a large randomised clinical trial, which is taking place in the UK, Republic of Ireland and India.

AIM: It has recruited 11,000 people to see whether regular aspirin use after early stage cancer can prevent the cancer from coming back and preventing deaths.

METHODOLOGY: The trial has been studying 2 different doses of aspirin (100mg and 300mg) versus placebo (a dummy tablet) and participants taking part in the trial till date have been randomly assigned one of these two doses or a placebo to take daily for 5 years



RATIONALE: The Add-Aspirin trial includes participants with breast, colorectal, gastro-oesophageal and prostate tumours which, together, accounts for approximately one third of all cancer cases and cancer deaths [1]. The selected disease sites are those for which (i) the evidence relating to potential benefit of aspirin is strongest; (ii) the potential impact is large (common cancers with large numbers of cases diagnosed at an early stage, or where outcomes of curative treatment are particularly poor); and (iii) recruitment is feasible.

It is an ongoing research so we don't have results about this trial yet but it was very interesting to see and interact with the patients undergoing the trial.